Evidence map›Paper›PMID 39231242›Full record

ReviewScience translational medicine2024

Precision adjuvants for pediatric vaccines.

Anjali Singh, César Boggiano, Dwight E Yin, Laura Polakowski, Sai P Majji, Wolfgang W Leitner, Ofer Levy, Kristina De Paris

Abstract readReview
In one paragraph

Review in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anjali SinghDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0009-0008-1191-2992
César BoggianoDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0000-0002-5503-8335
Dwight E YinDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0000-0002-8599-1004
Laura PolakowskiDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0000-0002-5476-7632
Sai P MajjiMaternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20817, USA.
Wolfgang W LeitnerDivision of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0000-0003-3125-5922
Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-5859-1945
Kristina De ParisDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5199-3004

Funding

Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responsesP01AI117915 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE PARIS, KRISTINA, PERMAR, SALLIE R. · 2015 to 2024
$21.2M
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infantsP01AI178377 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kristina De Paris · 2023 to 2026
$7.7M
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES75N93023C00040 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DOWLING, DAVID JAMES · 2023 to 2025
$4.3M
NIAID NIH HHS 75N93019C00044NIAID NIH HHS 75N93023C00040NIAID NIH HHS P01 AI117915NIAID NIH HHS P01 AI178377NIAID NIH HHS U19 AI168643
6 · The paper itself

Abstract

Elucidating optimal vaccine adjuvants for harnessing age-specific immune pathways to enhance magnitude, breadth, and durability of immunogenicity remains a key gap area in pediatric vaccine design. A better understanding of age-specific adjuvants will inform precision discovery and development of safe and effective vaccines for protecting children from preventable infectious diseases.

Indexed as

Precision MedicineVaccinesAdjuvants, ImmunologicAdjuvants, VaccineChildHumansPediatricsAdjuvants, ImmunologicAdjuvants, VaccineVaccines

Identifiers

PMID39231242
PMCPMC11911902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.